CTM have higher stemness, survival and metastatic growth possibility (30-50 times) than single CTCs. Only our team can identify, and quantify the expression of PDL1 on the surface of CTM and the proportion of peripheral immune cells (myeloid-derived suppressor cells (MDSCs) or Treg cell to CTC/CTM ratio)